nodes	percent_of_prediction	percent_of_DWPC	metapath
Rimonabant—CYP3A4—bone cancer	0.902	1	CbGaD
Rimonabant—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00381	0.064	CbGpPWpGaD
Rimonabant—Memory loss—Cisplatin—bone cancer	0.00292	0.0761	CcSEcCtD
Rimonabant—Mood alteration NOS—Methotrexate—bone cancer	0.00234	0.0611	CcSEcCtD
Rimonabant—CNR1—GPCRs, Other—GRM1—bone cancer	0.00223	0.0374	CbGpPWpGaD
Rimonabant—CNR1—GPCRs, Other—SMO—bone cancer	0.00157	0.0264	CbGpPWpGaD
Rimonabant—CNR2—G alpha (i) signalling events—RGS1—bone cancer	0.00153	0.0257	CbGpPWpGaD
Rimonabant—CNR2—G alpha (i) signalling events—GRM4—bone cancer	0.00153	0.0257	CbGpPWpGaD
Rimonabant—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00149	0.0249	CbGpPWpGaD
Rimonabant—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00148	0.0248	CbGpPWpGaD
Rimonabant—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00147	0.0246	CbGpPWpGaD
Rimonabant—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0014	0.0235	CbGpPWpGaD
Rimonabant—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.0014	0.0235	CbGpPWpGaD
Rimonabant—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00125	0.021	CbGpPWpGaD
Rimonabant—CNR1—G alpha (i) signalling events—RGS1—bone cancer	0.0012	0.0202	CbGpPWpGaD
Rimonabant—CNR1—G alpha (i) signalling events—GRM4—bone cancer	0.0012	0.0202	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—EIF2S1—bone cancer	0.00114	0.0191	CbGpPWpGaD
Rimonabant—Infection—Carboplatin—bone cancer	0.00104	0.027	CcSEcCtD
Rimonabant—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000967	0.0162	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—GRM4—bone cancer	0.000929	0.0156	CbGpPWpGaD
Rimonabant—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000909	0.0153	CbGpPWpGaD
Rimonabant—Hiccups—Cisplatin—bone cancer	0.000858	0.0224	CcSEcCtD
Rimonabant—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000853	0.0143	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—GRM1—bone cancer	0.000805	0.0135	CbGpPWpGaD
Rimonabant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000792	0.0133	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—GRM4—bone cancer	0.000729	0.0122	CbGpPWpGaD
Rimonabant—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000723	0.0121	CbGpPWpGaD
Rimonabant—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000714	0.012	CbGpPWpGaD
Rimonabant—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000707	0.0119	CbGpPWpGaD
Rimonabant—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000686	0.0115	CbGpPWpGaD
Rimonabant—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00068	0.0114	CbGpPWpGaD
Rimonabant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000677	0.0114	CbGpPWpGaD
Rimonabant—Amnesia—Cisplatin—bone cancer	0.000663	0.0173	CcSEcCtD
Rimonabant—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000658	0.011	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000636	0.0107	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—GRM1—bone cancer	0.000632	0.0106	CbGpPWpGaD
Rimonabant—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000631	0.0106	CbGpPWpGaD
Rimonabant—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00063	0.0106	CbGpPWpGaD
Rimonabant—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000604	0.0101	CbGpPWpGaD
Rimonabant—Irritability—Cisplatin—bone cancer	0.000594	0.0155	CcSEcCtD
Rimonabant—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000581	0.00975	CbGpPWpGaD
Rimonabant—CNR2—GPCR ligand binding—SMO—bone cancer	0.000567	0.00952	CbGpPWpGaD
Rimonabant—Cramp muscle—Cisplatin—bone cancer	0.000561	0.0146	CcSEcCtD
Rimonabant—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000539	0.00904	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—GRM4—bone cancer	0.000525	0.00881	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—RGS1—bone cancer	0.000525	0.00881	CbGpPWpGaD
Rimonabant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000522	0.00876	CbGpPWpGaD
Rimonabant—Abdominal discomfort—Cisplatin—bone cancer	0.000516	0.0134	CcSEcCtD
Rimonabant—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000486	0.00815	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—GRM4—bone cancer	0.000477	0.008	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—RGS1—bone cancer	0.000477	0.008	CbGpPWpGaD
Rimonabant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000463	0.00776	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—GRM1—bone cancer	0.000455	0.00764	CbGpPWpGaD
Rimonabant—CNR1—GPCR ligand binding—SMO—bone cancer	0.000445	0.00747	CbGpPWpGaD
Rimonabant—Hiccups—Epirubicin—bone cancer	0.00044	0.0115	CcSEcCtD
Rimonabant—Connective tissue disorder—Cisplatin—bone cancer	0.000423	0.011	CcSEcCtD
Rimonabant—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000416	0.00698	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—GRM1—bone cancer	0.000413	0.00693	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—RGS1—bone cancer	0.000412	0.00691	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—GRM4—bone cancer	0.000412	0.00691	CbGpPWpGaD
Rimonabant—Hiccups—Doxorubicin—bone cancer	0.000407	0.0106	CcSEcCtD
Rimonabant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000395	0.00663	CbGpPWpGaD
Rimonabant—Mediastinal disorder—Cisplatin—bone cancer	0.000388	0.0101	CcSEcCtD
Rimonabant—Malnutrition—Cisplatin—bone cancer	0.000375	0.00977	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—RGS1—bone cancer	0.000374	0.00628	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—GRM4—bone cancer	0.000374	0.00628	CbGpPWpGaD
Rimonabant—CNR1—BDNF signaling pathway—JUN—bone cancer	0.00036	0.00605	CbGpPWpGaD
Rimonabant—Muscle spasms—Cisplatin—bone cancer	0.00036	0.0094	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—GRM1—bone cancer	0.000357	0.00599	CbGpPWpGaD
Rimonabant—Tremor—Cisplatin—bone cancer	0.000351	0.00916	CcSEcCtD
Rimonabant—Lethargy—Methotrexate—bone cancer	0.000349	0.00909	CcSEcCtD
Rimonabant—Hot flush—Epirubicin—bone cancer	0.000342	0.00891	CcSEcCtD
Rimonabant—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000341	0.00572	CbGpPWpGaD
Rimonabant—Menopausal symptoms—Epirubicin—bone cancer	0.000339	0.00883	CcSEcCtD
Rimonabant—Hypoglycaemia—Epirubicin—bone cancer	0.000328	0.00854	CcSEcCtD
Rimonabant—Lethargy—Epirubicin—bone cancer	0.000326	0.0085	CcSEcCtD
Rimonabant—Irritability—Methotrexate—bone cancer	0.000326	0.0085	CcSEcCtD
Rimonabant—Convulsion—Cisplatin—bone cancer	0.000325	0.00847	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—GRM1—bone cancer	0.000324	0.00544	CbGpPWpGaD
Rimonabant—Mood swings—Methotrexate—bone cancer	0.000324	0.00844	CcSEcCtD
Rimonabant—Anxiety—Cisplatin—bone cancer	0.000318	0.00829	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000317	0.00826	CcSEcCtD
Rimonabant—Hot flush—Doxorubicin—bone cancer	0.000316	0.00824	CcSEcCtD
Rimonabant—Menopausal symptoms—Doxorubicin—bone cancer	0.000313	0.00817	CcSEcCtD
Rimonabant—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.00031	0.00521	CbGpPWpGaD
Rimonabant—Infection—Cisplatin—bone cancer	0.000304	0.00792	CcSEcCtD
Rimonabant—Hypoglycaemia—Doxorubicin—bone cancer	0.000303	0.0079	CcSEcCtD
Rimonabant—Mood swings—Epirubicin—bone cancer	0.000303	0.00789	CcSEcCtD
Rimonabant—Lethargy—Doxorubicin—bone cancer	0.000302	0.00787	CcSEcCtD
Rimonabant—Nervous system disorder—Cisplatin—bone cancer	0.0003	0.00782	CcSEcCtD
Rimonabant—Skin disorder—Cisplatin—bone cancer	0.000297	0.00775	CcSEcCtD
Rimonabant—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000296	0.00497	CbGpPWpGaD
Rimonabant—Hyperhidrosis—Cisplatin—bone cancer	0.000296	0.00771	CcSEcCtD
Rimonabant—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000294	0.00493	CbGpPWpGaD
Rimonabant—CNR2—GPCR downstream signaling—GNA11—bone cancer	0.000293	0.00492	CbGpPWpGaD
Rimonabant—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000292	0.0049	CbGpPWpGaD
Rimonabant—Anorexia—Cisplatin—bone cancer	0.000292	0.0076	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—SMO—bone cancer	0.000291	0.00489	CbGpPWpGaD
Rimonabant—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00029	0.00486	CbGpPWpGaD
Rimonabant—Abdominal discomfort—Methotrexate—bone cancer	0.000283	0.00738	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—GRM4—bone cancer	0.000282	0.00472	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—RGS1—bone cancer	0.000282	0.00472	CbGpPWpGaD
Rimonabant—Mood swings—Doxorubicin—bone cancer	0.00028	0.0073	CcSEcCtD
Rimonabant—Influenza—Epirubicin—bone cancer	0.000276	0.0072	CcSEcCtD
Rimonabant—Paraesthesia—Cisplatin—bone cancer	0.000275	0.00716	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Methotrexate—bone cancer	0.000274	0.00715	CcSEcCtD
Rimonabant—CNR2—Signaling by GPCR—GNA11—bone cancer	0.000266	0.00447	CbGpPWpGaD
Rimonabant—Decreased appetite—Cisplatin—bone cancer	0.000266	0.00693	CcSEcCtD
Rimonabant—CNR2—GPCR downstream signaling—IL3—bone cancer	0.000266	0.00446	CbGpPWpGaD
Rimonabant—Gastrointestinal disorder—Cisplatin—bone cancer	0.000264	0.00689	CcSEcCtD
Rimonabant—Infestation—Methotrexate—bone cancer	0.000263	0.00686	CcSEcCtD
Rimonabant—Infestation NOS—Methotrexate—bone cancer	0.000263	0.00686	CcSEcCtD
Rimonabant—Depression—Methotrexate—bone cancer	0.000262	0.00684	CcSEcCtD
Rimonabant—Upper respiratory tract infection—Epirubicin—bone cancer	0.000257	0.00669	CcSEcCtD
Rimonabant—Influenza—Doxorubicin—bone cancer	0.000256	0.00666	CcSEcCtD
Rimonabant—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000251	0.00421	CbGpPWpGaD
Rimonabant—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000248	0.00416	CbGpPWpGaD
Rimonabant—Infestation—Epirubicin—bone cancer	0.000246	0.00642	CcSEcCtD
Rimonabant—Infestation NOS—Epirubicin—bone cancer	0.000246	0.00642	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—GRM1—bone cancer	0.000244	0.0041	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—IL3—bone cancer	0.000241	0.00405	CbGpPWpGaD
Rimonabant—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00024	0.00403	CbGpPWpGaD
Rimonabant—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000238	0.00399	CbGpPWpGaD
Rimonabant—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000238	0.00619	CcSEcCtD
Rimonabant—Sinusitis—Epirubicin—bone cancer	0.000231	0.00602	CcSEcCtD
Rimonabant—CNR1—GPCR downstream signaling—GNA11—bone cancer	0.00023	0.00386	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—SMO—bone cancer	0.000229	0.00383	CbGpPWpGaD
Rimonabant—Infestation—Doxorubicin—bone cancer	0.000228	0.00594	CcSEcCtD
Rimonabant—Infestation NOS—Doxorubicin—bone cancer	0.000228	0.00594	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—RGS1—bone cancer	0.000221	0.00371	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—GRM4—bone cancer	0.000221	0.00371	CbGpPWpGaD
Rimonabant—Hypoaesthesia—Epirubicin—bone cancer	0.00022	0.00574	CcSEcCtD
Rimonabant—Asthenia—Cisplatin—bone cancer	0.00022	0.00572	CcSEcCtD
Rimonabant—Connective tissue disorder—Epirubicin—bone cancer	0.000217	0.00567	CcSEcCtD
Rimonabant—Angiopathy—Methotrexate—bone cancer	0.000214	0.00559	CcSEcCtD
Rimonabant—Sinusitis—Doxorubicin—bone cancer	0.000214	0.00557	CcSEcCtD
Rimonabant—Mediastinal disorder—Methotrexate—bone cancer	0.000213	0.00555	CcSEcCtD
Rimonabant—Diarrhoea—Cisplatin—bone cancer	0.000209	0.00546	CcSEcCtD
Rimonabant—CNR1—Signaling by GPCR—GNA11—bone cancer	0.000209	0.00351	CbGpPWpGaD
Rimonabant—CNR1—GPCR downstream signaling—IL3—bone cancer	0.000209	0.0035	CbGpPWpGaD
Rimonabant—Mental disorder—Methotrexate—bone cancer	0.000207	0.0054	CcSEcCtD
Rimonabant—Malnutrition—Methotrexate—bone cancer	0.000206	0.00536	CcSEcCtD
Rimonabant—Hypoaesthesia—Doxorubicin—bone cancer	0.000204	0.00531	CcSEcCtD
Rimonabant—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000203	0.00341	CbGpPWpGaD
Rimonabant—Connective tissue disorder—Doxorubicin—bone cancer	0.000201	0.00524	CcSEcCtD
Rimonabant—Angiopathy—Epirubicin—bone cancer	0.000201	0.00523	CcSEcCtD
Rimonabant—Mediastinal disorder—Epirubicin—bone cancer	0.000199	0.0052	CcSEcCtD
Rimonabant—Vomiting—Cisplatin—bone cancer	0.000195	0.00507	CcSEcCtD
Rimonabant—Mental disorder—Epirubicin—bone cancer	0.000194	0.00505	CcSEcCtD
Rimonabant—Rash—Cisplatin—bone cancer	0.000193	0.00503	CcSEcCtD
Rimonabant—Dermatitis—Cisplatin—bone cancer	0.000193	0.00502	CcSEcCtD
Rimonabant—Malnutrition—Epirubicin—bone cancer	0.000193	0.00502	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—GRM1—bone cancer	0.000192	0.00321	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—IL3—bone cancer	0.000189	0.00318	CbGpPWpGaD
Rimonabant—Tension—Epirubicin—bone cancer	0.000189	0.00492	CcSEcCtD
Rimonabant—Nervousness—Epirubicin—bone cancer	0.000187	0.00487	CcSEcCtD
Rimonabant—Angiopathy—Doxorubicin—bone cancer	0.000186	0.00484	CcSEcCtD
Rimonabant—Muscle spasms—Epirubicin—bone cancer	0.000185	0.00482	CcSEcCtD
Rimonabant—Mediastinal disorder—Doxorubicin—bone cancer	0.000184	0.00481	CcSEcCtD
Rimonabant—Nausea—Cisplatin—bone cancer	0.000182	0.00474	CcSEcCtD
Rimonabant—Mental disorder—Doxorubicin—bone cancer	0.000179	0.00467	CcSEcCtD
Rimonabant—Convulsion—Methotrexate—bone cancer	0.000178	0.00465	CcSEcCtD
Rimonabant—Malnutrition—Doxorubicin—bone cancer	0.000178	0.00464	CcSEcCtD
Rimonabant—Tension—Doxorubicin—bone cancer	0.000175	0.00456	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000174	0.00453	CcSEcCtD
Rimonabant—Nervousness—Doxorubicin—bone cancer	0.000173	0.00451	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—SMO—bone cancer	0.000172	0.00289	CbGpPWpGaD
Rimonabant—Muscle spasms—Doxorubicin—bone cancer	0.000171	0.00446	CcSEcCtD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000167	0.00281	CbGpPWpGaD
Rimonabant—Convulsion—Epirubicin—bone cancer	0.000167	0.00435	CcSEcCtD
Rimonabant—Infection—Methotrexate—bone cancer	0.000167	0.00435	CcSEcCtD
Rimonabant—Nervous system disorder—Methotrexate—bone cancer	0.000165	0.00429	CcSEcCtD
Rimonabant—Anxiety—Epirubicin—bone cancer	0.000163	0.00426	CcSEcCtD
Rimonabant—Skin disorder—Methotrexate—bone cancer	0.000163	0.00425	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000163	0.00424	CcSEcCtD
Rimonabant—Hyperhidrosis—Methotrexate—bone cancer	0.000162	0.00423	CcSEcCtD
Rimonabant—Dry mouth—Epirubicin—bone cancer	0.00016	0.00418	CcSEcCtD
Rimonabant—Anorexia—Methotrexate—bone cancer	0.00016	0.00417	CcSEcCtD
Rimonabant—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000158	0.00265	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—GNA11—bone cancer	0.000157	0.00264	CbGpPWpGaD
Rimonabant—Infection—Epirubicin—bone cancer	0.000156	0.00407	CcSEcCtD
Rimonabant—Convulsion—Doxorubicin—bone cancer	0.000154	0.00402	CcSEcCtD
Rimonabant—Nervous system disorder—Epirubicin—bone cancer	0.000154	0.00402	CcSEcCtD
Rimonabant—Skin disorder—Epirubicin—bone cancer	0.000153	0.00398	CcSEcCtD
Rimonabant—Hyperhidrosis—Epirubicin—bone cancer	0.000152	0.00396	CcSEcCtD
Rimonabant—Insomnia—Methotrexate—bone cancer	0.000152	0.00396	CcSEcCtD
Rimonabant—Anxiety—Doxorubicin—bone cancer	0.000151	0.00394	CcSEcCtD
Rimonabant—Paraesthesia—Methotrexate—bone cancer	0.000151	0.00393	CcSEcCtD
Rimonabant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000151	0.00393	CcSEcCtD
Rimonabant—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000151	0.00253	CbGpPWpGaD
Rimonabant—Anorexia—Epirubicin—bone cancer	0.00015	0.0039	CcSEcCtD
Rimonabant—Dry mouth—Doxorubicin—bone cancer	0.000148	0.00387	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—ATF1—bone cancer	0.000146	0.00245	CbGpPWpGaD
Rimonabant—Decreased appetite—Methotrexate—bone cancer	0.000146	0.0038	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Methotrexate—bone cancer	0.000145	0.00378	CcSEcCtD
Rimonabant—Fatigue—Methotrexate—bone cancer	0.000145	0.00377	CcSEcCtD
Rimonabant—Infection—Doxorubicin—bone cancer	0.000144	0.00376	CcSEcCtD
Rimonabant—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000143	0.00239	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—IL3—bone cancer	0.000143	0.00239	CbGpPWpGaD
Rimonabant—Nervous system disorder—Doxorubicin—bone cancer	0.000143	0.00372	CcSEcCtD
Rimonabant—Insomnia—Epirubicin—bone cancer	0.000142	0.0037	CcSEcCtD
Rimonabant—Skin disorder—Doxorubicin—bone cancer	0.000141	0.00368	CcSEcCtD
Rimonabant—Paraesthesia—Epirubicin—bone cancer	0.000141	0.00368	CcSEcCtD
Rimonabant—Hyperhidrosis—Doxorubicin—bone cancer	0.000141	0.00366	CcSEcCtD
Rimonabant—Anorexia—Doxorubicin—bone cancer	0.000139	0.00361	CcSEcCtD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000138	0.00231	CbGpPWpGaD
Rimonabant—Gastrointestinal pain—Methotrexate—bone cancer	0.000137	0.00358	CcSEcCtD
Rimonabant—Decreased appetite—Epirubicin—bone cancer	0.000137	0.00356	CcSEcCtD
Rimonabant—Gastrointestinal disorder—Epirubicin—bone cancer	0.000136	0.00354	CcSEcCtD
Rimonabant—Fatigue—Epirubicin—bone cancer	0.000135	0.00353	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—SMO—bone cancer	0.000135	0.00226	CbGpPWpGaD
Rimonabant—Abdominal pain—Methotrexate—bone cancer	0.000133	0.00346	CcSEcCtD
Rimonabant—Insomnia—Doxorubicin—bone cancer	0.000131	0.00343	CcSEcCtD
Rimonabant—Paraesthesia—Doxorubicin—bone cancer	0.000131	0.0034	CcSEcCtD
Rimonabant—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000129	0.00216	CbGpPWpGaD
Rimonabant—Gastrointestinal pain—Epirubicin—bone cancer	0.000128	0.00335	CcSEcCtD
Rimonabant—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000128	0.00214	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000126	0.00212	CbGpPWpGaD
Rimonabant—Decreased appetite—Doxorubicin—bone cancer	0.000126	0.00329	CcSEcCtD
Rimonabant—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000126	0.00211	CbGpPWpGaD
Rimonabant—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000126	0.00327	CcSEcCtD
Rimonabant—Fatigue—Doxorubicin—bone cancer	0.000125	0.00327	CcSEcCtD
Rimonabant—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000125	0.00209	CbGpPWpGaD
Rimonabant—Abdominal pain—Epirubicin—bone cancer	0.000124	0.00324	CcSEcCtD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000124	0.00208	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—GNA11—bone cancer	0.000123	0.00207	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TGFBR2—bone cancer	0.000122	0.00205	CbGpPWpGaD
Rimonabant—Asthenia—Methotrexate—bone cancer	0.00012	0.00314	CcSEcCtD
Rimonabant—Gastrointestinal pain—Doxorubicin—bone cancer	0.000119	0.0031	CcSEcCtD
Rimonabant—Pruritus—Methotrexate—bone cancer	0.000119	0.0031	CcSEcCtD
Rimonabant—Abdominal pain—Doxorubicin—bone cancer	0.000115	0.003	CcSEcCtD
Rimonabant—Diarrhoea—Methotrexate—bone cancer	0.000115	0.00299	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—IGF1R—bone cancer	0.000115	0.00193	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—ATF1—bone cancer	0.000115	0.00193	CbGpPWpGaD
Rimonabant—Asthenia—Epirubicin—bone cancer	0.000113	0.00294	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—IL3—bone cancer	0.000112	0.00188	CbGpPWpGaD
Rimonabant—Pruritus—Epirubicin—bone cancer	0.000111	0.0029	CcSEcCtD
Rimonabant—Dizziness—Methotrexate—bone cancer	0.000111	0.00289	CcSEcCtD
Rimonabant—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.00011	0.00185	CbGpPWpGaD
Rimonabant—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000109	0.00183	CbGpPWpGaD
Rimonabant—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000108	0.00181	CbGpPWpGaD
Rimonabant—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000108	0.00181	CbGpPWpGaD
Rimonabant—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000108	0.00181	CbGpPWpGaD
Rimonabant—Diarrhoea—Epirubicin—bone cancer	0.000107	0.0028	CcSEcCtD
Rimonabant—Vomiting—Methotrexate—bone cancer	0.000107	0.00278	CcSEcCtD
Rimonabant—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000107	0.00179	CbGpPWpGaD
Rimonabant—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000107	0.00179	CbGpPWpGaD
Rimonabant—Rash—Methotrexate—bone cancer	0.000106	0.00276	CcSEcCtD
Rimonabant—Dermatitis—Methotrexate—bone cancer	0.000106	0.00276	CcSEcCtD
Rimonabant—Headache—Methotrexate—bone cancer	0.000105	0.00274	CcSEcCtD
Rimonabant—Asthenia—Doxorubicin—bone cancer	0.000104	0.00272	CcSEcCtD
Rimonabant—Dizziness—Epirubicin—bone cancer	0.000104	0.00271	CcSEcCtD
Rimonabant—Pruritus—Doxorubicin—bone cancer	0.000103	0.00268	CcSEcCtD
Rimonabant—Vomiting—Epirubicin—bone cancer	9.99e-05	0.0026	CcSEcCtD
Rimonabant—Nausea—Methotrexate—bone cancer	9.97e-05	0.0026	CcSEcCtD
Rimonabant—Diarrhoea—Doxorubicin—bone cancer	9.95e-05	0.00259	CcSEcCtD
Rimonabant—Rash—Epirubicin—bone cancer	9.91e-05	0.00258	CcSEcCtD
Rimonabant—Dermatitis—Epirubicin—bone cancer	9.9e-05	0.00258	CcSEcCtD
Rimonabant—Headache—Epirubicin—bone cancer	9.84e-05	0.00257	CcSEcCtD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.75e-05	0.00164	CbGpPWpGaD
Rimonabant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.75e-05	0.00164	CbGpPWpGaD
Rimonabant—Dizziness—Doxorubicin—bone cancer	9.61e-05	0.00251	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—TGFBR2—bone cancer	9.57e-05	0.00161	CbGpPWpGaD
Rimonabant—Nausea—Epirubicin—bone cancer	9.33e-05	0.00243	CcSEcCtD
Rimonabant—CYP1A2—Biological oxidations—GSTP1—bone cancer	9.24e-05	0.00155	CbGpPWpGaD
Rimonabant—Vomiting—Doxorubicin—bone cancer	9.24e-05	0.00241	CcSEcCtD
Rimonabant—Rash—Doxorubicin—bone cancer	9.17e-05	0.00239	CcSEcCtD
Rimonabant—Dermatitis—Doxorubicin—bone cancer	9.16e-05	0.00239	CcSEcCtD
Rimonabant—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	9.12e-05	0.00153	CbGpPWpGaD
Rimonabant—Headache—Doxorubicin—bone cancer	9.11e-05	0.00237	CcSEcCtD
Rimonabant—CNR1—Signaling Pathways—IGF1R—bone cancer	9.01e-05	0.00151	CbGpPWpGaD
Rimonabant—Nausea—Doxorubicin—bone cancer	8.63e-05	0.00225	CcSEcCtD
Rimonabant—CNR2—Signaling Pathways—KIT—bone cancer	8.32e-05	0.0014	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—BRAF—bone cancer	7.82e-05	0.00131	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NDUFA12—bone cancer	7.65e-05	0.00128	CbGpPWpGaD
Rimonabant—CNR2—Signaling by GPCR—EGFR—bone cancer	7.58e-05	0.00127	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NDUFA12—bone cancer	7.58e-05	0.00127	CbGpPWpGaD
Rimonabant—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.13e-05	0.0012	CbGpPWpGaD
Rimonabant—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.04e-05	0.00118	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MDM2—bone cancer	6.56e-05	0.0011	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—KIT—bone cancer	6.53e-05	0.0011	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NDUFA12—bone cancer	6.48e-05	0.00109	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—NT5C3A—bone cancer	6.34e-05	0.00106	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—NT5C3A—bone cancer	6.28e-05	0.00105	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—BRAF—bone cancer	6.14e-05	0.00103	CbGpPWpGaD
Rimonabant—CNR1—Signaling by GPCR—EGFR—bone cancer	5.95e-05	0.000998	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—JUN—bone cancer	5.7e-05	0.000956	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—MMP9—bone cancer	5.54e-05	0.00093	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—NT5C3A—bone cancer	5.37e-05	0.000901	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MDM2—bone cancer	5.14e-05	0.000863	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NDUFA12—bone cancer	5e-05	0.000839	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—EGFR—bone cancer	4.48e-05	0.000752	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—JUN—bone cancer	4.47e-05	0.00075	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—MMP9—bone cancer	4.35e-05	0.00073	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—NT5C3A—bone cancer	4.14e-05	0.000695	CbGpPWpGaD
Rimonabant—CNR2—Signaling Pathways—TP53—bone cancer	3.76e-05	0.000631	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—EGFR—bone cancer	3.52e-05	0.00059	CbGpPWpGaD
Rimonabant—CNR1—Signaling Pathways—TP53—bone cancer	2.95e-05	0.000495	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—ENO2—bone cancer	2.78e-05	0.000466	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—ENO2—bone cancer	2.75e-05	0.000462	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—DHFR—bone cancer	2.58e-05	0.000432	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—DHFR—bone cancer	2.55e-05	0.000428	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GNA11—bone cancer	2.41e-05	0.000404	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GNA11—bone cancer	2.39e-05	0.0004	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—ENO2—bone cancer	2.35e-05	0.000394	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—CYP3A4—bone cancer	2.18e-05	0.000366	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—DHFR—bone cancer	2.18e-05	0.000366	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—CYP3A4—bone cancer	2.16e-05	0.000363	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.15e-05	0.000361	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GNA11—bone cancer	2.04e-05	0.000342	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—GSTP1—bone cancer	1.87e-05	0.000313	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—GSTP1—bone cancer	1.85e-05	0.00031	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—CYP3A4—bone cancer	1.85e-05	0.00031	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.84e-05	0.000309	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—ENO2—bone cancer	1.81e-05	0.000304	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—DHFR—bone cancer	1.68e-05	0.000282	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—GSTP1—bone cancer	1.58e-05	0.000265	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GNA11—bone cancer	1.57e-05	0.000264	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—GSTP1—bone cancer	1.22e-05	0.000205	CbGpPWpGaD
Rimonabant—CYP2D6—Metabolism—PTGS2—bone cancer	9.67e-06	0.000162	CbGpPWpGaD
Rimonabant—CYP2C9—Metabolism—PTGS2—bone cancer	9.58e-06	0.000161	CbGpPWpGaD
Rimonabant—CYP1A2—Metabolism—PTGS2—bone cancer	8.19e-06	0.000137	CbGpPWpGaD
Rimonabant—CYP3A4—Metabolism—PTGS2—bone cancer	6.32e-06	0.000106	CbGpPWpGaD
